Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial
Reymond, N., Speranza, C., Gruet, P., Seewald, W., King, J. N. Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial. J. vet. Pharmacol. Therap. 35, 175–183. Robenacoxib is a member of the coxib class of nonsteroidal anti‐inflammatory drugs...
Gespeichert in:
| Veröffentlicht in: | Journal of veterinary pharmacology and therapeutics 2012-04, Vol.35 (2), p.175-183 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 183 |
|---|---|
| container_issue | 2 |
| container_start_page | 175 |
| container_title | Journal of veterinary pharmacology and therapeutics |
| container_volume | 35 |
| creator | REYMOND, N SPERANZA, C GRUET, P SEEWALD, W KING, J. N |
| description | Reymond, N., Speranza, C., Gruet, P., Seewald, W., King, J. N. Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial. J. vet. Pharmacol. Therap. 35, 175–183. Robenacoxib is a member of the coxib class of nonsteroidal anti‐inflammatory drugs (NSAID), with high selectivity for the cyclooxygenase (COX)‐2 isoform of COX. In this study, the efficacy and tolerability of robenacoxib were compared with those of carprofen in canine osteoarthritis in a multi‐centre, prospective, randomized, blinded, positive‐controlled noninferiority clinical trial. Both drugs were administered orally once daily at recommended dosages: robenacoxib at 1–2 mg/kg (n = 125 dogs) and racemic carprofen at 2–4 mg/kg (n = 63 dogs) for a total of 12 weeks. The efficacy of the test compounds was assessed by veterinary investigators and owners using numerical rating scales at baseline and days 7, 14, 28, 56 and 84. In both groups, all scores were significantly (P |
| doi_str_mv | 10.1111/j.1365-2885.2011.01297.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_926504277</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1093444187</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5297-34e04a48a4253a5a5c0c8d6c6bfe2aa36b7221eac8862edc9b1e42bb69879c443</originalsourceid><addsrcrecordid>eNqNkk1v1DAQhiMEokvhL4BvcCDBX3EcIQ6oogVUAQLacrMmzoR6SeLWzpZdfj0OKXtE-GJL87xjjR9nGWG0YGm9WBdMqDLnWpcFp4wVlPG6KrZ3stW-cDdbUSZpXlVaHGQPYlxTSoVm7H52wJnUtBZ8lV1_9g2OYP3WNeQmFsRCuAq-w5F0PpDpEskUEKYBx4n4LpVHNyLxcUIPYboMbnLxJQESYGz94H5h-5yMPkEdBudTeUds70ZnoU-dHPQPs3sd9BEf3e6H2dnxm69Hb_PTjyfvjl6f5rZMs-RCIpUgNUheCiihtNTqVlnVdMgBhGoqzhmC1VpxbG3dMJS8aVStq9pKKQ6zp0vfNM71BuNkBhct9j2M6DfR1FyVVPKqSuSzf5IsPZWUkukZ1Qtqg48xYGeughsg7BJkZjVmbWYDZjZgZjXmjxqzTdHHt7dsmgHbffCviwS8WoCfrsfdfzc2788_zaeUz5e8S3K2-zyEH0ZVoirNxYcTw9W5ulDlN0MT_2ThO_AGvgcXzdkXPv8ZStPIWojfa622fA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1093444187</pqid></control><display><type>article</type><title>Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>REYMOND, N ; SPERANZA, C ; GRUET, P ; SEEWALD, W ; KING, J. N</creator><creatorcontrib>REYMOND, N ; SPERANZA, C ; GRUET, P ; SEEWALD, W ; KING, J. N</creatorcontrib><description>Reymond, N., Speranza, C., Gruet, P., Seewald, W., King, J. N. Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial. J. vet. Pharmacol. Therap. 35, 175–183. Robenacoxib is a member of the coxib class of nonsteroidal anti‐inflammatory drugs (NSAID), with high selectivity for the cyclooxygenase (COX)‐2 isoform of COX. In this study, the efficacy and tolerability of robenacoxib were compared with those of carprofen in canine osteoarthritis in a multi‐centre, prospective, randomized, blinded, positive‐controlled noninferiority clinical trial. Both drugs were administered orally once daily at recommended dosages: robenacoxib at 1–2 mg/kg (n = 125 dogs) and racemic carprofen at 2–4 mg/kg (n = 63 dogs) for a total of 12 weeks. The efficacy of the test compounds was assessed by veterinary investigators and owners using numerical rating scales at baseline and days 7, 14, 28, 56 and 84. In both groups, all scores were significantly (P < 0.0001) improved compared with baseline at all time points (days 7–84). Robenacoxib had noninferior efficacy to carprofen for the primary endpoint, the global functional disability, both for all dogs and for the subgroup of dogs in which robenacoxib was not administered during meals. Noninferiority was also demonstrated for three of six veterinary investigator secondary endpoints and four of six owner efficacy endpoints. For haematology and clinical chemistry variables, there were some significant differences from baseline levels but no differences between groups. There were no differences between groups in the frequencies of adverse events, which were reported in 46% dogs with robenacoxib and 52% with carprofen (P = 0.44), which were most frequently mild events affecting the gastrointestinal tract. In conclusion, noninferior efficacy and tolerability of robenacoxib compared with carprofen was demonstrated in dogs with osteoarthritis.</description><identifier>ISSN: 0140-7783</identifier><identifier>EISSN: 1365-2885</identifier><identifier>DOI: 10.1111/j.1365-2885.2011.01297.x</identifier><identifier>PMID: 21480932</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Animals ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Carbazoles - therapeutic use ; Diphenylamine - analogs & derivatives ; Diphenylamine - therapeutic use ; Dog Diseases - drug therapy ; Dogs ; Female ; gastrointestinal system ; hematology ; Male ; nonsteroidal anti-inflammatory agents ; oral administration ; osteoarthritis ; Osteoarthritis - drug therapy ; Osteoarthritis - veterinary ; Phenylacetates - therapeutic use ; rating scales</subject><ispartof>Journal of veterinary pharmacology and therapeutics, 2012-04, Vol.35 (2), p.175-183</ispartof><rights>2011 Blackwell Publishing Ltd</rights><rights>2011 Blackwell Publishing Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5297-34e04a48a4253a5a5c0c8d6c6bfe2aa36b7221eac8862edc9b1e42bb69879c443</citedby><cites>FETCH-LOGICAL-c5297-34e04a48a4253a5a5c0c8d6c6bfe2aa36b7221eac8862edc9b1e42bb69879c443</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2885.2011.01297.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2885.2011.01297.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21480932$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>REYMOND, N</creatorcontrib><creatorcontrib>SPERANZA, C</creatorcontrib><creatorcontrib>GRUET, P</creatorcontrib><creatorcontrib>SEEWALD, W</creatorcontrib><creatorcontrib>KING, J. N</creatorcontrib><title>Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial</title><title>Journal of veterinary pharmacology and therapeutics</title><addtitle>J Vet Pharmacol Ther</addtitle><description>Reymond, N., Speranza, C., Gruet, P., Seewald, W., King, J. N. Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial. J. vet. Pharmacol. Therap. 35, 175–183. Robenacoxib is a member of the coxib class of nonsteroidal anti‐inflammatory drugs (NSAID), with high selectivity for the cyclooxygenase (COX)‐2 isoform of COX. In this study, the efficacy and tolerability of robenacoxib were compared with those of carprofen in canine osteoarthritis in a multi‐centre, prospective, randomized, blinded, positive‐controlled noninferiority clinical trial. Both drugs were administered orally once daily at recommended dosages: robenacoxib at 1–2 mg/kg (n = 125 dogs) and racemic carprofen at 2–4 mg/kg (n = 63 dogs) for a total of 12 weeks. The efficacy of the test compounds was assessed by veterinary investigators and owners using numerical rating scales at baseline and days 7, 14, 28, 56 and 84. In both groups, all scores were significantly (P < 0.0001) improved compared with baseline at all time points (days 7–84). Robenacoxib had noninferior efficacy to carprofen for the primary endpoint, the global functional disability, both for all dogs and for the subgroup of dogs in which robenacoxib was not administered during meals. Noninferiority was also demonstrated for three of six veterinary investigator secondary endpoints and four of six owner efficacy endpoints. For haematology and clinical chemistry variables, there were some significant differences from baseline levels but no differences between groups. There were no differences between groups in the frequencies of adverse events, which were reported in 46% dogs with robenacoxib and 52% with carprofen (P = 0.44), which were most frequently mild events affecting the gastrointestinal tract. In conclusion, noninferior efficacy and tolerability of robenacoxib compared with carprofen was demonstrated in dogs with osteoarthritis.</description><subject>Animals</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Carbazoles - therapeutic use</subject><subject>Diphenylamine - analogs & derivatives</subject><subject>Diphenylamine - therapeutic use</subject><subject>Dog Diseases - drug therapy</subject><subject>Dogs</subject><subject>Female</subject><subject>gastrointestinal system</subject><subject>hematology</subject><subject>Male</subject><subject>nonsteroidal anti-inflammatory agents</subject><subject>oral administration</subject><subject>osteoarthritis</subject><subject>Osteoarthritis - drug therapy</subject><subject>Osteoarthritis - veterinary</subject><subject>Phenylacetates - therapeutic use</subject><subject>rating scales</subject><issn>0140-7783</issn><issn>1365-2885</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkk1v1DAQhiMEokvhL4BvcCDBX3EcIQ6oogVUAQLacrMmzoR6SeLWzpZdfj0OKXtE-GJL87xjjR9nGWG0YGm9WBdMqDLnWpcFp4wVlPG6KrZ3stW-cDdbUSZpXlVaHGQPYlxTSoVm7H52wJnUtBZ8lV1_9g2OYP3WNeQmFsRCuAq-w5F0PpDpEskUEKYBx4n4LpVHNyLxcUIPYboMbnLxJQESYGz94H5h-5yMPkEdBudTeUds70ZnoU-dHPQPs3sd9BEf3e6H2dnxm69Hb_PTjyfvjl6f5rZMs-RCIpUgNUheCiihtNTqVlnVdMgBhGoqzhmC1VpxbG3dMJS8aVStq9pKKQ6zp0vfNM71BuNkBhct9j2M6DfR1FyVVPKqSuSzf5IsPZWUkukZ1Qtqg48xYGeughsg7BJkZjVmbWYDZjZgZjXmjxqzTdHHt7dsmgHbffCviwS8WoCfrsfdfzc2788_zaeUz5e8S3K2-zyEH0ZVoirNxYcTw9W5ulDlN0MT_2ThO_AGvgcXzdkXPv8ZStPIWojfa622fA</recordid><startdate>201204</startdate><enddate>201204</enddate><creator>REYMOND, N</creator><creator>SPERANZA, C</creator><creator>GRUET, P</creator><creator>SEEWALD, W</creator><creator>KING, J. N</creator><general>Blackwell Publishing Ltd</general><scope>FBQ</scope><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope></search><sort><creationdate>201204</creationdate><title>Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial</title><author>REYMOND, N ; SPERANZA, C ; GRUET, P ; SEEWALD, W ; KING, J. N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5297-34e04a48a4253a5a5c0c8d6c6bfe2aa36b7221eac8862edc9b1e42bb69879c443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Carbazoles - therapeutic use</topic><topic>Diphenylamine - analogs & derivatives</topic><topic>Diphenylamine - therapeutic use</topic><topic>Dog Diseases - drug therapy</topic><topic>Dogs</topic><topic>Female</topic><topic>gastrointestinal system</topic><topic>hematology</topic><topic>Male</topic><topic>nonsteroidal anti-inflammatory agents</topic><topic>oral administration</topic><topic>osteoarthritis</topic><topic>Osteoarthritis - drug therapy</topic><topic>Osteoarthritis - veterinary</topic><topic>Phenylacetates - therapeutic use</topic><topic>rating scales</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>REYMOND, N</creatorcontrib><creatorcontrib>SPERANZA, C</creatorcontrib><creatorcontrib>GRUET, P</creatorcontrib><creatorcontrib>SEEWALD, W</creatorcontrib><creatorcontrib>KING, J. N</creatorcontrib><collection>AGRIS</collection><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of veterinary pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>REYMOND, N</au><au>SPERANZA, C</au><au>GRUET, P</au><au>SEEWALD, W</au><au>KING, J. N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial</atitle><jtitle>Journal of veterinary pharmacology and therapeutics</jtitle><addtitle>J Vet Pharmacol Ther</addtitle><date>2012-04</date><risdate>2012</risdate><volume>35</volume><issue>2</issue><spage>175</spage><epage>183</epage><pages>175-183</pages><issn>0140-7783</issn><eissn>1365-2885</eissn><abstract>Reymond, N., Speranza, C., Gruet, P., Seewald, W., King, J. N. Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial. J. vet. Pharmacol. Therap. 35, 175–183. Robenacoxib is a member of the coxib class of nonsteroidal anti‐inflammatory drugs (NSAID), with high selectivity for the cyclooxygenase (COX)‐2 isoform of COX. In this study, the efficacy and tolerability of robenacoxib were compared with those of carprofen in canine osteoarthritis in a multi‐centre, prospective, randomized, blinded, positive‐controlled noninferiority clinical trial. Both drugs were administered orally once daily at recommended dosages: robenacoxib at 1–2 mg/kg (n = 125 dogs) and racemic carprofen at 2–4 mg/kg (n = 63 dogs) for a total of 12 weeks. The efficacy of the test compounds was assessed by veterinary investigators and owners using numerical rating scales at baseline and days 7, 14, 28, 56 and 84. In both groups, all scores were significantly (P < 0.0001) improved compared with baseline at all time points (days 7–84). Robenacoxib had noninferior efficacy to carprofen for the primary endpoint, the global functional disability, both for all dogs and for the subgroup of dogs in which robenacoxib was not administered during meals. Noninferiority was also demonstrated for three of six veterinary investigator secondary endpoints and four of six owner efficacy endpoints. For haematology and clinical chemistry variables, there were some significant differences from baseline levels but no differences between groups. There were no differences between groups in the frequencies of adverse events, which were reported in 46% dogs with robenacoxib and 52% with carprofen (P = 0.44), which were most frequently mild events affecting the gastrointestinal tract. In conclusion, noninferior efficacy and tolerability of robenacoxib compared with carprofen was demonstrated in dogs with osteoarthritis.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21480932</pmid><doi>10.1111/j.1365-2885.2011.01297.x</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-7783 |
| ispartof | Journal of veterinary pharmacology and therapeutics, 2012-04, Vol.35 (2), p.175-183 |
| issn | 0140-7783 1365-2885 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_926504277 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Animals Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Carbazoles - therapeutic use Diphenylamine - analogs & derivatives Diphenylamine - therapeutic use Dog Diseases - drug therapy Dogs Female gastrointestinal system hematology Male nonsteroidal anti-inflammatory agents oral administration osteoarthritis Osteoarthritis - drug therapy Osteoarthritis - veterinary Phenylacetates - therapeutic use rating scales |
| title | Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T13%3A34%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Robenacoxib%20vs.%20carprofen%20for%20the%20treatment%20of%20canine%20osteoarthritis;%20a%20randomized,%20noninferiority%20clinical%20trial&rft.jtitle=Journal%20of%20veterinary%20pharmacology%20and%20therapeutics&rft.au=REYMOND,%20N&rft.date=2012-04&rft.volume=35&rft.issue=2&rft.spage=175&rft.epage=183&rft.pages=175-183&rft.issn=0140-7783&rft.eissn=1365-2885&rft_id=info:doi/10.1111/j.1365-2885.2011.01297.x&rft_dat=%3Cproquest_cross%3E1093444187%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1093444187&rft_id=info:pmid/21480932&rfr_iscdi=true |